All Posts Tagged With: "Herbal Remedy from Thailand"

H.R.T. from Longevity Plus

Linda’s comment:  I began taking the H.R.T. from  and happy that I did.  This is an awesome product….This H.R.T. isan herbal remedy  from Thailand.  Please read about it at the above web site.
Dr. Gordon’s Comments: What you must know about HRT, both kinds, the dangerous pharmaceutical version and the documented safe alternative herbal form, PUERARIA MIRIFICA. You can have happy menopausal patients without doubling their breast cancer recurrence rate. Just read this carefully and, if interested, ask Longevity Plus customer support to email you a packet of scientific information.

Anyone realizing that hormone therapy doubles recurrence of breast cancer should take the time to learn about the alternative to standard HRT that is Longevity Plus’s H.R.T. (Herbal Remedy from Thailand). Here we have epidemiological evidence that those consuming Pueraria Mirifica in their diet regularly have the lowest incidence of Breast Cancer according to the World Health Organization statistics.

Now your patients can have the improved quality of life that the ESTRIOL-like MIROESTROL component to H.R.T. provides without the increased risk of breast cancer associated with the pharmacological based HRT (Hormone Replacement Therapy) so widely used today in the US in spite of its known risks of heart disease and cancer.

Try H.R.T. on your next patient who has memory loss, insomnia, hot flashes, vaginal dryness and the other constellation of symptoms associated with menopause and see for yourself. Remember, the added ingredients in H.R.T. include the VITAL METHYLATION FACTORS like all 3 forms of Folic Acid and Methylcobalamin.  The published data about the more natural form of folic acid  5’MTHF shows it helps depression, even when antidepressants have not helped, and helps peripheral neuropathy, and improves memory, and helps to deal with endothelial vascular dysfunction ( vascular disease).

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute

 HRT Doubles Recurrence Risk in Breast Cancer Survivors
LONDON, March 25 — Breast cancer survivors treated with hormone replacement therapy had a more than two-fold increased risk of recurrence or a contralateral malignancy, according to long-term follow-up data from a randomized clinical trial.

•Note that this is one of the few randomized, controlled studies that have examined the risk of breast cancer recurrence associated with HRT.
Those randomized to HRT had five-year breast cancer rates of 22.2% compared with 8% in women who received best patient care for menopausal symptoms without hormone therapy, Lars Holmberg, M.D., Ph.D., of King’s College London, and colleagues, reported in the April 2 issue of the Journal of the National Cancer Institute.

“The results of the HABITS [Hormonal Replacement after Breast Cancer — Is It Safe?] trial indicate a substantial risk a new breast cancer event among breast cancer survivors using hormone therapy,” the authors concluded.

“Our results further suggest that hormone therapy not only induces and promotes breast cancer but may also stimulate the growth of tumor microdeposits in breast cancer survivors,” they added.

Despite the statistically significant impact of hormone therapy on breast cancer risk, the authors said more data from randomized studies are needed to define the risk and to clear up inconsistencies in prior studies.

However, Kathleen Pritchard, M.D., a breast cancer specialist at Sunnybrook Odette Cancer Center in Toronto, said in an accompanying editorial that the study “suggests quite definitively that there is a statistically significantly increased risk of recurrence in women given HRT following diagnosis of breast cancer.”

Persistent questions about the potential risks and benefits of HRT in breast cancer survivors provided impetus for several observational studies and analyses of case series. More recently, data from the Women’s Health Initiative and the Million Women Study provided additional compelling evidence of an increased risk of breast cancer among HRT users, the King’s College authors said.